American Journal of Clinical Dermatology

, Volume 7, Issue 1, pp 7–12 | Cite as

Topical Macrolide Immunomodulators

A Role in the Treatment of Vitiligo?
  • Milan Tjioe
  • Wynand H.P.M. Vissers
  • Marie-Jeanne P. Gerritsen
Current Opinion


Recently, topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. With the growing interest in this new line of topical immunosuppressants, research into the efficacy of these medicines in other T-cell-mediated skin diseases, such as psoriasis, lichen planus, and even vitiligo, is expanding rapidly. It is generally accepted that autoimmune factors play an important role in vitiligo. In this article, the possible use and mechanism of topical macrolide immunomodulators in the treatment of vitiligo are discussed, together with the current state of clinical studies and case reports. These limited reports indicate that topical macrolide immunomodulators may play a role in the treatment of vitiligo, particularly in areas where use of potent corticosteroids is contraindicated.


Tacrolimus Atopic Dermatitis Macrolides Vitiligo Lichen Planus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Le Poole C, van den Wijngaard RM, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996; 148 (4): 1219–28PubMedGoogle Scholar
  2. 2.
    Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol. 2000; 191 (4): 407–16PubMedCrossRefGoogle Scholar
  3. 3.
    Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997; 84 (3): 223–43PubMedCrossRefGoogle Scholar
  4. 4.
    Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet. 1994; 55 (5): 981–90PubMedGoogle Scholar
  5. 5.
    Njoo MD, Westerhof W. Vitiligo: pathogenesis and treatment. Am J Clin Dermatol. 2001; 2 (3): 167–81PubMedCrossRefGoogle Scholar
  6. 6.
    van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients: destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest. 2000; 80 (8): 1299–309PubMedCrossRefGoogle Scholar
  7. 7.
    van den Wijngaard R, Wankowicz-Kalinska A, Pals S, et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest. 2001; 81 (8): 1061–7PubMedGoogle Scholar
  8. 8.
    Montes LF, Abulafia J, Wilbom WH, et al. Value of histopathology in vitiligo. Int J Dermatol. 2003; 42 (1): 57–61PubMedCrossRefGoogle Scholar
  9. 9.
    Lemer AB. Vitiligo. J Invest Dermatol. 1959; 32 (2 Pt 2): 285-310Google Scholar
  10. 10.
    Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol. 1991; 97 (6): 1081–5PubMedCrossRefGoogle Scholar
  11. 11.
    Schallreuter KU. Effectiveness of pseudocatalase formulations in vitiligo. Clin Exp Dermatol. 2003; 28 (5): 562–3PubMedCrossRefGoogle Scholar
  12. 12.
    Moellmann G, Klein-Angerer S, Scollay DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol. 1982; 79 (5): 321–30PubMedCrossRefGoogle Scholar
  13. 13.
    Hafez M, Sharaf L, Abd et-Nabi SM. The genetics of vitiligo. Acta Derm Venereol. 1983; 63 (3): 249–51PubMedGoogle Scholar
  14. 14.
    Kim SM, Chung HS, Hann SK. The genetics of vitiligo in Korean patients. Int J Dermatol. 1998; 37 (12): 908–10PubMedCrossRefGoogle Scholar
  15. 15.
    Le Poole IC, Das PK, van den Wijngaard RM, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 1993; 2 (4): 145–53PubMedCrossRefGoogle Scholar
  16. 16.
    Tjioe M, Gerritsen MJ, Juhlin L, et al. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol. 2002; 82 (5): 369–72PubMedCrossRefGoogle Scholar
  17. 17.
    Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol. 1998; 134 (12): 1532–40PubMedCrossRefGoogle Scholar
  18. 18.
    British Photodermatology Group guidelines for PUVA. Br J Dermatol J 1994; 130 (2): 246–55CrossRefGoogle Scholar
  19. 19.
    Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer. 1994; 73 (11): 2759–64PubMedCrossRefGoogle Scholar
  20. 20.
    Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 2001; 44 (5): 755–61PubMedCrossRefGoogle Scholar
  21. 21.
    Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997; 133 (12): 1525–8PubMedCrossRefGoogle Scholar
  22. 22.
    Tjice M, Smits T, Van De Kerkhof PCM, et al. The differential effect of broad band versus narrow band UVB with respect to photodamage and cutaneous inflammation. Exp Dermatol. 2003; 12 (6): 729–33CrossRefGoogle Scholar
  23. 23.
    Njoo MD, Westerhof W, Bos JD, et al. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol. 1998; 134 (12): 1543–9PubMedCrossRefGoogle Scholar
  24. 24.
    Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002; 46 (4): 495–504PubMedCrossRefGoogle Scholar
  25. 25.
    Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol. 1998; 139 (6): 992–6PubMedCrossRefGoogle Scholar
  26. 26.
    Rappersberger K, Meingassner JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996; 106 (4): 701–10PubMedCrossRefGoogle Scholar
  27. 27.
    Lener EV, Brieva J, Schachter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol. 2001; 137 (4): 419–22PubMedGoogle Scholar
  28. 28.
    Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol. 1999; 140 (2): 338–42PubMedCrossRefGoogle Scholar
  29. 29.
    Richter-Hintz D, Schuppe HC, Homey B, et al. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol. 2000; 42 (2 Pt 1): 304–5PubMedCrossRefGoogle Scholar
  30. 30.
    Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol. 1998; 139 (4): 755–7PubMedCrossRefGoogle Scholar
  31. 31.
    Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002; 47 (5): 789–91PubMedCrossRefGoogle Scholar
  32. 32.
    Reynolds NJ, Al Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 2002; 27 (7): 555–61PubMedCrossRefGoogle Scholar
  33. 33.
    Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology. 2000; 47 (2-3): 203–13PubMedCrossRefGoogle Scholar
  34. 34.
    Bornhovd EC, Schuller E, Bieber T, et al. Immunosuppressive macrolides and their use in dermatology [in German]. Hautarzt. 2000; 51 (9): 646–54PubMedCrossRefGoogle Scholar
  35. 35.
    Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002; 46 (2): 228–41PubMedCrossRefGoogle Scholar
  36. 36.
    Castanet J, Ortonne JP. Pathophysiology of vitiligo. Clin Dermatol. 1997; 15 (6): 845–51CrossRefGoogle Scholar
  37. 37.
    Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998; 188 (6): 1203–8PubMedCrossRefGoogle Scholar
  38. 38.
    Yeo UC, Yang YS, Park KB, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci. 1999; 19 (3): 182–8PubMedCrossRefGoogle Scholar
  39. 39.
    Caixia T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci. 1999; 21 (1): 59–62PubMedCrossRefGoogle Scholar
  40. 40.
    Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004; 51 (1): 52–61PubMedCrossRefGoogle Scholar
  41. 41.
    Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003; 139 (5): 581–5PubMedCrossRefGoogle Scholar
  42. 42.
    Tanghetti EA. Tacrolimus ointment 0.1 % produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis. 2003; 71 (2): 158–62PubMedGoogle Scholar
  43. 43.
    Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol. 2003; 139 (5): 571–4PubMedCrossRefGoogle Scholar
  44. 44.
    Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed. 2003; 19 (1): 35–6PubMedCrossRefGoogle Scholar
  45. 45.
    Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology. 2002; 205 (3): 301–3PubMedCrossRefGoogle Scholar
  46. 46.
    Mayoral FA, Gonzalez C, Shah NS, et al. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology. 2003; 207 (3): 322–3PubMedCrossRefGoogle Scholar
  47. 47.
    Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998; 111 (3): 396–8PubMedCrossRefGoogle Scholar
  48. 48.
    Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy [letter]. Br J Dermatol. 2002; 146 (2): 342PubMedCrossRefGoogle Scholar
  49. 49.
    Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001; 144 (3): 50–13CrossRefGoogle Scholar
  50. 50.
    Boguniewicz M, Fiedler VC, Rainier S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998; 102 (4 Pt 1): 637–44PubMedCrossRefGoogle Scholar
  51. 51.
    Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001; 44 (1 Suppl.): S28–38PubMedCrossRefGoogle Scholar
  52. 52.
    Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000; 136 (8): 999–1006PubMedCrossRefGoogle Scholar
  53. 53.
    Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004; 30 (2 Pt 1): 130–5PubMedCrossRefGoogle Scholar
  54. 54.
    Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004; 140 (9): 1065–9PubMedCrossRefGoogle Scholar
  55. 55.
    Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000; 9 (3): 165–9PubMedCrossRefGoogle Scholar
  56. 56.
    Wester RC, Maibach HI. In vivo percutaneous absorption. In: Marzulli FN, Maibach HI, editors. Dermatoxicology. 2nd ed. Washington, DC: Hemisphere Publishing Corporation, 1983: 131–46Google Scholar
  57. 57.
    Gutzmer R, Volker B, Kapp A, et al. Successful topical treatment of cutaneous sarcoidosis with tacrolimus [in German]. Hautarzt. 2003; 54 (12): 1193–7PubMedCrossRefGoogle Scholar
  58. 58.
    Katoh N, Mihara H, Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol. 2002; 147 (1): 154–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Milan Tjioe
    • 1
  • Wynand H.P.M. Vissers
    • 1
  • Marie-Jeanne P. Gerritsen
  1. 1.Department of DermatologyRadboud University Nijmegen Medical CentreNijmegenThe Netherlands

Personalised recommendations